Optimi Health Corp. (CSE:OPTI)
6.94
+0.01 (0.14%)
Sep 18, 2026, 3:59 PM EST
Optimi Health Revenue
Optimi Health had revenue of 140.20K CAD in the quarter ending June 30, 2026, a decrease of -28.61%. This brings the company's revenue in the last twelve months to 175.67K, down -67.95% year-over-year. In the fiscal year ending September 30, 2025, Optimi Health had annual revenue of 426.30K with 9.35% growth.
Revenue (ttm)
175.67K
Revenue Growth
-67.95%
P/S Ratio
226.20
Revenue / Employee
n/a
Employees
n/a
Market Cap
39.74M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Sep 30, 2025 | 426.30K | 36.45K | 9.35% |
| Sep 30, 2024 | 389.85K | 208.76K | 115.28% |
| Sep 30, 2023 | 181.09K | 100.37K | 124.35% |
| Sep 30, 2022 | 80.72K | - | - |
| Sep 30, 2021 | - | - | - |
| Sep 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| iAnthus Capital Holdings | 197.59M |
| 1CM Inc. | 75.45M |
| Vext Science | 71.97M |
| Rubicon Organics | 64.23M |
| LSL Pharma Group | 41.83M |
| MediPharm Labs | 41.46M |
| Medicure | 32.08M |
| ZYUS Life Sciences | 374.00K |
Optimi Health News
- 3 days ago - Optimi Health Plans Phase 3 Trial Of MDMA-Assisted Therapy For PTSD - Nasdaq
- 3 days ago - Optimi Health Expands Clinical Program with Phase 3 Trial Evaluating MDMA-Assisted Therapy for Post-Traumatic Stress Disorder - Financial Post
- 3 days ago - Optimi Health Expands Clinical Program with Phase 3 Trial Evaluating MDMA-Assisted Therapy for Post-Traumatic Stress Disorder - GlobeNewsWire
- 8 days ago - Optimi Health Transcript: H.C. Wainwright 28th Annual Global Investment Conference - Transcripts
- 9 days ago - Optimi Health to initiate Phase 2 trial of psilocybin-assisted therapy for MDD - TheFly
- 9 days ago - Optimi Health To Initiate Phase 2 Psilocybin Trial For Major Depression - Nasdaq
- 9 days ago - Optimi Health to Initiate Phase 2 Clinical Trial Evaluating Psilocybin-Assisted Therapy for Major Depressive Disorder - Financial Post
- 9 days ago - Optimi Health to Initiate Phase 2 Clinical Trial Evaluating Psilocybin-Assisted Therapy for Major Depressive Disorder - GlobeNewsWire